TY - JOUR
T1 - Theranostics in prostaatkanker
AU - Privé, Bastiaan M.
AU - Muselaers, Constantijn H. J.
AU - Peters, Steffie M. B.
AU - Timmermans, Bart
AU - Westdorp, Harm
AU - Franken, Mira D.
AU - Vis, André N.
AU - Janssen, Marcel J. R.
AU - Oprea-Lager, Daniela E.
AU - Nagarajah, James
N1 - Publisher Copyright: © The Author(s) 2024.
PY - 2024/3/1
Y1 - 2024/3/1
N2 - 177Lu-PSMA is a novel therapy in patients with metastatic castration-resistant prostate carcinoma (mCRPC). The radiolabeled drug is administered intravenously, usually in 4–6 cycles, in which β‑radiation induces intracellular DNA damage and cell death of PSMA-expressing prostate cancer cells. The γ‑decay of the radionuclide can be used for imaging and dosimetry. An international phase III study showed that end stage mCRPC patients that received 177Lu-PSMA had a survival benefit (15.3 vs. 11.3 months; p < 0.001). Moreover, several studies suggest that ~25% of these heavily pre-treated patients respond better and likely have a longer survival benefit. The most important side effects are: grade I–II fatigue (~40%) and xerostomia (~40%), which are mostly transient. Grade III–IV CTCAE hematologic toxicity (thrombocytopenia, leukopenia) was seen in ~8% of patients. Recently, the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the drug for patients with end stage prostate cancer. Currently, there are several studies investigating if patients in an earlier stage of the disease, metastatic hormone-sensitive or hormone-naïf, can also benefit from therapy with 177Lu-PSMA.
AB - 177Lu-PSMA is a novel therapy in patients with metastatic castration-resistant prostate carcinoma (mCRPC). The radiolabeled drug is administered intravenously, usually in 4–6 cycles, in which β‑radiation induces intracellular DNA damage and cell death of PSMA-expressing prostate cancer cells. The γ‑decay of the radionuclide can be used for imaging and dosimetry. An international phase III study showed that end stage mCRPC patients that received 177Lu-PSMA had a survival benefit (15.3 vs. 11.3 months; p < 0.001). Moreover, several studies suggest that ~25% of these heavily pre-treated patients respond better and likely have a longer survival benefit. The most important side effects are: grade I–II fatigue (~40%) and xerostomia (~40%), which are mostly transient. Grade III–IV CTCAE hematologic toxicity (thrombocytopenia, leukopenia) was seen in ~8% of patients. Recently, the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the drug for patients with end stage prostate cancer. Currently, there are several studies investigating if patients in an earlier stage of the disease, metastatic hormone-sensitive or hormone-naïf, can also benefit from therapy with 177Lu-PSMA.
KW - Lutetium
KW - Metastases
KW - PSMA
KW - Prostate carcinoma
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85186409816&partnerID=8YFLogxK
U2 - 10.1007/s13629-024-00423-7
DO - 10.1007/s13629-024-00423-7
M3 - Article
SN - 2211-3037
VL - 14
SP - 63
EP - 72
JO - Tijdschrift voor Urologie
JF - Tijdschrift voor Urologie
IS - 2-3
ER -